Dna Group (T.R.) Balance Sheet Health
Financial Health criteria checks 6/6
Dna Group (T.R.) has a total shareholder equity of ₪98.3M and total debt of ₪0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₪99.6M and ₪1.3M respectively.
Key information
0%
Debt to equity ratio
₪0
Debt
| Interest coverage ratio | n/a |
| Cash | ₪67.33m |
| Equity | ₪98.30m |
| Total liabilities | ₪1.30m |
| Total assets | ₪99.60m |
Recent financial health updates
We Think Dna Group (T.R.) (TLV:DNA) Can Afford To Drive Business Growth
Apr 12
Dna Group (T.R.) (TLV:DNA) Is In A Strong Position To Grow Its Business
Jul 07We Think Dna Group (T.R.) (TLV:DNA) Can Easily Afford To Drive Business Growth
Jan 24We're Not Worried About D.N.A Biomedical Solutions' (TLV:DNA) Cash Burn
Oct 07Recent updates
Dna Group (T.R.)'s (TLV:DNA) Earnings Might Not Be As Promising As They Seem
Sep 02We Think Dna Group (T.R.) (TLV:DNA) Can Afford To Drive Business Growth
Apr 12Dna Group (T.R.) (TLV:DNA) Is In A Strong Position To Grow Its Business
Jul 07We Think Dna Group (T.R.) (TLV:DNA) Can Easily Afford To Drive Business Growth
Jan 24We're Not Worried About D.N.A Biomedical Solutions' (TLV:DNA) Cash Burn
Oct 07Financial Position Analysis
Short Term Liabilities: DNA's short term assets (₪67.5M) exceed its short term liabilities (₪666.0K).
Long Term Liabilities: DNA's short term assets (₪67.5M) exceed its long term liabilities (₪634.0K).
Debt to Equity History and Analysis
Debt Level: DNA is debt free.
Reducing Debt: DNA had no debt 5 years ago.
Debt Coverage: DNA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: DNA has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:51 |
| End of Day Share Price | 2024/12/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dna Group (T.R.) Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|